Trial Profile
Open-Label, Randomized, Single Dose, 3-Period Crossover to Evaluate the Relative Bioavailability and Food-Effect on Pharmacokinetics of Alternative 10 mg/mL Liquid Formulation ACY-1215 (Rocolinostat) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Ricolinostat (Primary)
- Indications Lymphoma; Multiple myeloma
- Focus Pharmacokinetics
- Sponsors Acetylon Pharmaceuticals
- 10 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Mar 2014 New trial record